ADC Therapeutics (ADCT) Gains from Investment Securities: 2018-2024
Historic Gains from Investment Securities for ADC Therapeutics (ADCT) over the last 7 years, with Dec 2024 value amounting to $1.2 million.
- ADC Therapeutics' Gains from Investment Securities rose 102.43% to $279,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$497,000, marking a year-over-year increase of 95.68%. This contributed to the annual value of $1.2 million for FY2024, which is 334.00% up from last year.
- ADC Therapeutics' Gains from Investment Securities amounted to $1.2 million in FY2024, which was up 334.00% from -$497,000 recorded in FY2023.
- ADC Therapeutics' Gains from Investment Securities' 5-year high stood at $1.2 million during FY2024, with a 5-year trough of -$11.5 million in FY2022.
- Moreover, its 3-year median value for Gains from Investment Securities was -$497,000 (2023), whereas its average is -$3.6 million.
- As far as peak fluctuations go, ADC Therapeutics' Gains from Investment Securities tumbled by 1,714,356.04% in 2022, and later soared by 334.00% in 2024.
- Yearly analysis of 5 years shows ADC Therapeutics' Gains from Investment Securities stood at -$29 in 2020, then slumped by 2,213.79% to -$671 in 2021, then slumped by 1,714,356.04% to -$11.5 million in 2022, then spiked by 95.68% to -$497,000 in 2023, then skyrocketed by 334.00% to $1.2 million in 2024.